Last reviewed · How we verify
Cerebrovascular Occlusion — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Iopidine | APRACLONIDINE | Harrow Health | alpha-Adrenergic Agonist | Alpha-2A adrenergic receptor | 1987-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- · 1 drug in Cerebrovascular Occlusion
- Harrow Health · 1 drug in Cerebrovascular Occlusion
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Cerebrovascular Occlusion:
- Cerebrovascular Occlusion treatment updates — RSS
- Cerebrovascular Occlusion treatment updates — Atom
- Cerebrovascular Occlusion treatment updates — JSON
Cite this brief
Drug Landscape (2026). Cerebrovascular Occlusion — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/cerebrovascular-occlusion. Accessed 2026-06-10.
Related
- Cerebrovascular Occlusion full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing